10-K: SelectQuote Shifts to Healthcare, Reports FY25 Profit

Sentiment:

Annual Report 21 August 2025 5:11 PM

SelectQuote, a leading insurance distributor, pivots to healthcare services, achieving net income in fiscal year 2025 despite a decline in its core Senior insurance segment.

Capital raiseOn February 10, 2025, the company completed a $350.0 million Senior Non-Convertible Preferred Stock transaction with NL Monarch Holdings LLC (Morgan Stanley) and NL Monarch Holdings II LLC (Bain Capital).Net proceeds of $337.9 million were received from this transaction.The proceeds were primarily used to repay $260.0 million of outstanding Term Loan balance, $4.9 million of accrued Term Loan interest, $13.0 million of transaction costs, and $40.0 million of the Revolving Credit Facility balance, with $20.0 million allocated to fund operations.The transaction also involved the issuance of 350,000 shares of Senior Non-Convertible Preferred Stock and up to 30,833,333 warrants to purchase common stock (Senior Non-Convertible Preferred Stock Warrants).

Summary

Total revenue increased by 16% to $1.53 billion for the year ended June 30, 2025, up from $1.32 billion in 2024.
Net income was $47.58 million for FY2025, a significant improvement from a net loss of $34.13 million in FY2024 and $58.54 million in FY2023.
Healthcare Services revenue surged by 57% to $742.7 million in FY2025, primarily driven by a 31% increase in SelectRx members to over 108,000.
Commissions and other services revenue decreased by 7% to $797.84 million in FY2025, mainly due to a $51.5 million decrease in Senior commissions revenue.
Approved policies in the Senior segment decreased by 4% to 663,169 in FY2025.
The Lifetime Value (LTV) per Medicare Advantage (MA) approved policy decreased by 3% to $884 in FY225, attributed to carrier mix changes and shifts away from upfront payment contracts, alongside persistency deterioration from recent plan terminations.
Life segment revenue increased by 10% to $173.0 million, primarily from a $14.0 million increase in final expense revenue.
Marketing and advertising expenses decreased by 11% to $319.51 million, due to a $31.5 million decrease in lead costs and improved close rates in Senior.
Selling, general, and administrative expenses increased by 17% to $164.44 million, driven by higher compensation costs related to SelectRx growth and a $4.2 million impairment charge for the InsideResponse intangible asset.
Interest expense, net, decreased by 15% to $79.39 million, following a securitization transaction and the use of Senior Non-Convertible Preferred Stock proceeds to repay $260.0 million of outstanding Term Loans.
The company completed a $350.0 million Senior Non-Convertible Preferred Stock transaction, receiving net proceeds of $337.9 million, used for debt repayment and operations.

Sentiment

Score: 7

Explanation: The company achieved net income after two years of losses, driven by strong growth in its strategic Healthcare Services segment. While the core Senior segment experienced a decline in revenue and LTV, the overall financial position improved, and significant debt was repaid through new financing. The strategic pivot towards healthcare services and continued investment in technology are positive long-term indicators, despite ongoing legal challenges and a declining core segment.

Positives

Achieved net income of $47.58 million in FY2025, a significant turnaround from prior year losses.
Healthcare Services segment demonstrated robust growth, with pharmacy revenue increasing 57% and SelectRx members growing 31%.
Successfully reduced total debt obligations from $683.3 million in FY2024 to $385.1 million in FY2025 through strategic financing and debt repayment.
Improved overall close rates in the Senior segment by 11% and increased productivity per agent by 24%, despite a decrease in average productive agents.
Maintains long-standing, deeply integrated relationships with leading insurance carriers, including UnitedHealthcare, Humana, and Aetna, which account for significant portions of total revenue.
Proprietary technology platform, integrating AI and data science, optimizes marketing spend, lead routing, and agent performance, enhancing efficiency and customer retention.
Expanded processing capacity for SelectRx with a new fulfillment facility in Olathe, Kansas, supporting future growth in healthcare services.

Negatives

Senior segment revenue decreased by 8% and approved policies declined by 4% in FY2025, indicating challenges in the core insurance distribution business.
Lifetime Value (LTV) per Medicare Advantage approved policy decreased by 3% due to carrier mix changes, shifts from upfront payment contracts, and deterioration in persistency from recent plan terminations.
Selling, general, and administrative expenses increased by 17%, partly due to a $4.2 million non-cash impairment charge related to the InsideResponse acquisition.
The company is subject to ongoing legal proceedings, including a Department of Justice action alleging False Claims Act violations, which could result in substantial monetary damages and negative publicity.
The company's common stock price has significantly declined since its IPO, with a cumulative total return of $8.81 on a $100 investment from May 2020 to June 2025.

Risks

Reliance on a limited number of insurance carrier partners, with potential for relationship termination or failure to develop new ones.
Changes in the health insurance market, product offerings, commission rates, and underwriting practices by insurance carriers.
Competition from government-run health insurance exchanges, other brokers, and carriers selling directly to consumers.
Dependence on revenue from the Senior segment and potential downturns in the senior health and life insurance industries.
Inability to develop new offerings, achieve increased consumer adoption, or penetrate new vertical markets successfully.
Risks associated with third-party products, including potential product liability claims for pharmacy products causing injury, illness, or death.
Dependence on obtaining a large quantity of quality insurance sales leads cost-effectively and converting them to sales.
Inability to attract, integrate, and retain qualified personnel, including agents and pharmacy staff.
Risks related to the accuracy and timeliness of commission reports from insurance carriers and potential credit losses if carriers fail.
Fluctuations in financial results due to seasonality, particularly the Medicare annual enrollment period (AEP).
Inability to adequately protect intellectual property, leading to competitive harm or costly disputes.
Disruptions or failures of technological infrastructure and platform, including cybersecurity breaches or attacks.
Non-compliance with complex and evolving laws and regulations governing insurance activities, healthcare services, privacy, and marketing practices.
Existing and future indebtedness could adversely affect business operations and access to additional capital.
Issues related to the development and use of artificial intelligence (AI) could give rise to legal and regulatory action or damage reputation.

Future Outlook

The company's strategy is focused on delivering more comprehensive and personalized healthcare solutions, leveraging its existing customer base and distribution model to expand its healthcare services business, including pharmacy services and chronic care management. It aims to maximize lifetime value by investing in agent experience, customer care, carrier relationships, pre-AEP outreach, and technology. The company plans to continue optimizing its agent force through training and technology, deepen consumer penetration through cross-selling, and grow its Healthcare Services segment by expanding product offerings and adding new business lines for Medicare beneficiaries. The company expects Medicare Advantage enrollment to continue rising to 64% by 2034, presenting a significant market opportunity.

Management Comments

Our strategy is focused on delivering more comprehensive and personalized healthcare solutions that meet the evolving needs of our senior customers.
SelectQuote's value lies in our ability to engage the consumer, capture critical self-reported information in real-time, and then take action on that information to offer each consumer personalized solutions.
We believe providing personalized advice and guidance from policy research to enrollment is a key differentiator in the senior health market, as consumers tend to prefer or require more personalized attention to navigate increasingly complex and ever-changing coverage options.
Our business success is built upon a robust, proprietary technology platform that integrates over 40 years of data, advanced algorithms, and artificial intelligence (AI).
We believe carriers see our method of acquiring customers as scalable and efficient and, ultimately, as cost advantageous compared to their own models.
Our goal is to maximize LTVs, and we do so through strategies designed to maximize the revenue opportunity.
Investing in our agent force is a critical aspect of our growth strategy.
We aspire to be the premier navigation platform to proactively engage members within the complex landscape of healthcare products and services.

Industry Context

The U.S. healthcare and insurance distribution markets are undergoing significant digital transformation, with increasing consumer demand for price transparency and online comparison shopping. The aging U.S. population, particularly the Baby Boomer generation, is driving substantial growth in the senior health market, with Medicare Advantage plans gaining prominence. The pharmaceutical market also presents a large addressable opportunity. SelectQuote is positioning itself to capitalize on these trends by leveraging its technology-enabled direct-to-consumer model and expanding into healthcare services, aiming to improve health outcomes and lower costs for seniors. The company faces competition from traditional agents, online platforms, and direct carrier sales, necessitating continuous innovation in technology and customer engagement.

Comparison to Industry Standards

The company's direct-to-consumer (DTC) model, coupled with its technology and skilled agents, aims to differentiate itself from traditional insurance distributors and online-only offerings by providing greater transparency, choice, and personalized advice, which is a key differentiator in the complex senior health market.
SelectQuote's use of AI and machine learning models for lead acquisition, management, and customer engagement positions it to take advantage of accelerating digital transformation trends, potentially offering a cost advantage compared to traditional distribution models or even direct carrier models.
In the pharmaceutical market, SelectRx competes with closed-door and online pharmacies like Accudose Pharmacy and ExactCare Pharmacy, as well as traditional brick-and-mortar pharmacies such as Walgreens and Caremark CVS. SelectRx's Patient-Centered Pharmacy Home™ accreditation and focus on medication adherence for polypharmacy patients differentiate its service model.
The company's ability to retain more tenured agents during off-peak seasons and recruit fewer additional agents for AEP suggests an efficient talent management system compared to industry peers that might face higher seasonal turnover or recruitment costs.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	NA	Representative of NL Monarch Holdings LLC (Morgan Stanley)	2025-02-10	Appointment pursuant to Director Designation Agreement in connection with Senior Non-Convertible Preferred Stock investment.
Director	NA	Representative of NL Monarch Holdings II LLC (Bain Capital)	2025-02-10	Appointment pursuant to Director Designation Agreement in connection with Senior Non-Convertible Preferred Stock investment.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws/Certificate of Incorporation Provisions	The company's Certificate of Incorporation and Bylaws include anti-takeover provisions such as a classified Board of Directors (three classes, each serving three-year terms), requiring stockholder removal of directors only for cause by majority vote, and limiting stockholders' ability to call special meetings or act by written consent. Amendments to Bylaws require a two-thirds vote of outstanding voting stock.	NA	These provisions are designed to make it more difficult to acquire the company through tender offers or proxy contests, encouraging negotiation with the Board. They may discourage certain types of coercive takeover practices and bids considered inadequate by the Board, potentially protecting the company's ability to negotiate better terms for shareholders.
Delaware Anti-Takeover Statute (Section 203 DGCL)	The company is subject to Section 203 of the DGCL, which prohibits business combinations with an interested stockholder (15% or more voting stock) for three years unless certain conditions are met (e.g., Board approval, 85% ownership, or two-thirds stockholder vote). The company has not opted out of this provision.	NA	This provision is expected to have an anti-takeover effect, discouraging transactions not approved by the Board and potentially discouraging attempts that might result in a premium over the market price for common stock.
Corporate Opportunities Renunciation	The Certificate of Incorporation renounces any interest or expectancy in business opportunities presented to non-employee directors or their affiliates, unless expressly offered to the director solely in their capacity as a director of the company.	NA	This provision limits the company's claim to certain business opportunities that its non-employee directors may encounter, potentially allowing directors to pursue opportunities outside the company without breaching fiduciary duties.
Director and Officer Liability/Indemnification	The Certificate of Incorporation limits directors' personal liability for monetary damages for fiduciary duty breaches to the fullest extent permitted by DGCL. The company's Certificate of Incorporation and Bylaws require indemnification of directors and officers for expenses, liabilities, and losses incurred in legal proceedings related to their service, provided they acted in good faith and in the company's best interests. Indemnification agreements are also in place with each director and officer.	NA	These provisions may discourage stockholders from bringing lawsuits against directors for breach of fiduciary duty and may reduce the likelihood of derivative litigation, potentially affecting the company's and stockholders' investment to the extent costs of settlement and damage awards are paid under these provisions.
Exclusive Forum Provision	The Certificate of Incorporation designates Delaware state courts (or federal court for the District of Delaware) as the sole and exclusive forum for certain internal corporate claims, including derivative actions and breach of fiduciary duty claims.	NA	This provision aims to centralize litigation in a specific jurisdiction, potentially reducing legal costs and ensuring consistent application of Delaware law, but it may limit stockholders' choice of forum for certain disputes.
Cybersecurity Governance	The company has a formal enterprise risk management approach for cybersecurity, with Board-approved Information Security policies reviewed annually. The Audit Committee oversees the cybersecurity program, receiving quarterly updates from the Chief Information Officer and Director of Information Technology Security.	NA	This structured governance framework aims to enhance the company's ability to identify, protect against, detect, respond to, and recover from cybersecurity threats, demonstrating a commitment to safeguarding sensitive data and maintaining operational resilience.

Legal Proceedings

**Securities Class Actions and Stockholder Derivative Suit:** Two putative securities class action lawsuits (Hartel v. SelectQuote, Inc., et al. and West Palm Beach Police Pension Fund v. SelectQuote, Inc., et al.) were consolidated into In re SelectQuote, Inc. Securities Litigation, alleging securities fraud and misstatements/omissions in connection with the IPO. The court dismissed the second amended complaint on April 3, 2025, but plaintiffs filed a notice of appeal on May 5, 2025, which remains pending.
A stockholder derivative action (Jadlow v. Danker, et al.) was filed on March 25, 2022, against current and former directors and officers, alleging breach of fiduciary duty and other claims. This action is currently stayed pending the resolution of the motion to dismiss the Securities Class Action.
**DOJ Action (False Claims Act):** On May 1, 2025, the U.S. Attorneys Office for the District of Massachusetts filed a complaint partially intervening in a qui tam action (United States ex rel. Shea v. eHealth, Inc., et al.) against the company and competitors, alleging violations of the Federal False Claims Act due to improper sales and marketing practices. The company denies the allegations and plans to defend vigorously. A joint motion to dismiss the government's complaint was filed on August 19, 2025.
**New Securities Class Action:** On August 11, 2025, a new putative securities class action lawsuit (Pahlkotter v. SelectQuote, Inc., et al.) was filed against the company and three current/former executive officers, asserting claims related to the allegations in the DOJ Action.
The company believes none of these matters will have a material adverse effect on its operations, financial condition, or liquidity, but acknowledges they could be costly to defend and divert management attention.

Related Party Transactions

InsideResponse (a SelectQuote subsidiary) sells leads to a senior healthcare distribution platform partly owned by individuals related to a company shareholder or management. Revenue from this was less than $0.1 million for FY2025, FY2024, and FY2023.
The company purchased leads from this same senior healthcare distribution platform, with costs being immaterial for FY2025, FY2024, and FY2023.
The company acts as the Field Marketing Organization for this firm, with the net financial impact being immaterial for FY2025, FY2024, and FY2023.
SelectRx leases operating facilities in Monaca, PA, from an Executive Vice President of SelectRx. The company expects to incur $3.6 million in total rental payments over the initial ten-year term plus an additional five-year extension option.

Stakeholder Impact

**Shareholders:** Potential for increased value from the strategic shift to higher-growth healthcare services and improved net income. However, ongoing legal proceedings and a declining core Senior segment could introduce volatility and risk to share price. The Senior Non-Convertible Preferred Stock and associated warrants could dilute common shareholders' equity and influence future dividend policies.
**Employees:** The company's focus on attracting, training, and retaining agents and pharmacy personnel, along with competitive compensation and career paths, aims to foster a positive work environment. However, the de-emphasis on the Auto & Home business might lead to shifts in workforce allocation.
**Customers (Consumers):** The expansion into healthcare services (SelectRx, SPM, Healthcare Select) aims to provide more comprehensive, personalized, and accessible solutions, improving health outcomes and overall experience for senior customers. The technology-driven approach seeks to offer greater transparency and choice in insurance products.
**Insurance Carrier Partners:** The company's distribution capabilities remain a key channel for carriers, with efforts to deepen relationships through data gathering (health risk assessments) and improved policy persistency. However, changes in carrier sales strategies or underwriting practices could impact the company's business.
**Creditors:** The recent securitization and Senior Non-Convertible Preferred Stock transactions have significantly reduced outstanding term loans, improving the company's debt profile and compliance with covenants, which is positive for creditors. However, future capital needs and potential litigation outcomes remain factors.

Next Steps

Continue to invest in agent experience and customer care teams to enhance close rates, commissionable premium, and renewal/cross-sell revenue.
Negotiate more favorable terms with carrier partners.
Conduct pre-AEP outreach to Senior segment policyholders to understand emerging consumer decision-making trends.
Optimize marketing and lead acquisition spend through technology, data, and analytics.
Expand product offerings and add new business lines within Healthcare Services to provide needed services for Medicare beneficiaries.
Evaluate the impact of the 'One Big Beautiful Bill Act' legislation on consolidated financial statements, to be reflected in the three-month period ended September 30, 2025.
Respond to the government's complaint in the DOJ Action by October 20, 2025.
Issue the remaining 15% of Senior Non-Convertible Preferred Stock Warrants (Contingent Warrants) on January 2, 2026, subject to certain conditions.

Key Dates

Date	Description
1984-08-14	SelectQuote Insurance Services, the original operating company, was incorporated in California.
1985	Company founded as a direct-to-consumer term life insurance exchange platform.
1999-08-18	SelectQuote, Inc. was incorporated in Delaware as a holding company.
2010	Senior segment was launched.
2011	Auto & Home segment was launched.
2011	First wave of post-war Baby Boomer generation turned 65, increasing demand for senior insurance products.
2019-11-05	Company entered into the Senior Secured Credit Facility.
2020-05-21	Common stock commenced trading on the New York Stock Exchange (NYSE) under the symbol SLQT.
2021	Healthcare Services segment was launched.
2021-08-16	Putative securities class action lawsuit (Hartel v. SelectQuote, Inc., et al.) filed.
2021-10-07	Putative securities class action lawsuit (West Palm Beach Police Pension Fund v. SelectQuote, Inc., et al.) filed.
2022-04-01	Employee Stock Purchase Plan (ESPP) amended and restated.
2022-09-02	Hartel and WPBPPF Actions consolidated under In re SelectQuote, Inc. Securities Litigation.
2023-04-01	Employee Stock Purchase Plan (ESPP) suspended.
2023-04-23	CMS finalized rules impacting Medicare marketing and sales.
2023-09-13	Fiscal year 2021 tranche of PSUs vested at 13% of target.
2024	Launched SelectPatient Management (SPM) after acquiring an existing chronic care management platform.
2024-04-24	CMS adopted final rules placing limitations on compensation of Medicare product distributors.
2024-10-15	Company completed a $100.0 million securitization transaction and entered into a Note Purchase Agreement and Indenture.
2024-10-15	Company entered into the Eleventh Amendment to its Credit Agreement, extending maturity date of consenting Term Loans to September 30, 2027.
2025-02-10	Company entered into Senior Non-Convertible Preferred Stock Purchase Agreements for a $350.0 million investment.
2025-02-28	Company received proceeds from the issuance of Senior Non-Convertible Preferred Stock and Senior Non-Convertible Preferred Stock Warrants.
2025-03-01	New Olathe, Kansas pharmacy fulfillment facility commenced operations.
2025-05-01	U.S. Attorneys Office for the District of Massachusetts filed a complaint partially intervening in a qui tam action (DOJ Action) against the Company.
2025-05-05	Plaintiffs filed a notice of appeal for the dismissed second amended complaint in the Securities Class Action.
2025-06-30	End of fiscal year 2025.
2025-07-25	Company entered into the Thirteenth Amendment to its Credit Agreement, extending the Revolving Credit Facility Termination Date to September 30, 2027.
2025-07-31	Outstanding common stock was 172,816,730 shares.
2025-08-08	Plaintiffs filed a brief in support of their appeal in the Securities Class Action.
2025-08-11	Putative securities class action lawsuit (Pahlkotter v. SelectQuote, Inc., et al.) filed against the Company.
2025-08-13	Second Circuit granted joint stipulation dismissing Brookside Equity Partners LLC from the appeal in the Securities Class Action.
2025-08-19	Company and co-defendants filed a joint motion to dismiss the government's complaint in the DOJ Action.
2026-01-02	Company will issue remaining 15% of Senior Non-Convertible Preferred Stock Warrants (Contingent Warrants), subject to certain conditions.
2027-02-28	Pharmaceutical supply agreement requires minimum monthly purchases of approximately $12.7 million through this date.
2027-09-30	Extended maturity date for consenting Term Loans under the Eleventh Amendment and Revolving Credit Facility Termination Date under the Thirteenth Amendment.
2028-09-20	Anticipated repayment date for Class A and Class B Notes under the Indenture.
2039-10-20	Final legal maturity date for Class A and Class B Notes under the Indenture.

Recommendation

hold

SelectQuote's pivot to healthcare services, particularly the growth in SelectRx, is a positive strategic move that has contributed to a return to net income. The significant reduction in long-term debt through recent financing activities also strengthens the balance sheet. However, the core Senior insurance segment is experiencing declining revenue and LTV, indicating persistent challenges. The company faces multiple ongoing legal proceedings, including a DOJ action, which introduce significant uncertainty and potential financial liabilities. While the long-term strategy in healthcare services holds promise, the mixed performance in core segments and the legal overhang suggest a 'hold' recommendation, as investors should monitor the execution of the healthcare pivot and the resolution of legal matters before considering a stronger position.

Keywords

Insurance Distribution, Healthcare Services, Medicare Advantage, SelectRx, Senior Health Insurance, Life Insurance, Direct-to-Consumer, AI Technology, SEC Filing, 10-K, Financial Results, Debt Restructuring, Risk Management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.